## Wendy A Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128915/publications.pdf Version: 2024-02-01

		147786	161844
131	3,667	31	54
papers	citations	h-index	g-index
131	131	131	4957
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Glycemic Exposure Is Associated With Reduced Pulmonary Function in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2004, 27, 752-757.	8.6	262
2	Peripheral Arterial Disease and Risk of Cardiac Death in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2006, 29, 575-580.	8.6	195
3	Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2008, 51, 562-566.	6.3	149
4	Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: The Fremantle Diabetes Study. Diabetologia, 2006, 49, 2634-2641.	6.3	135
5	Longitudinal Predictors of Reduced Mobility and Physical Disability in Patients With Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2005, 28, 2441-2447.	8.6	124
6	Incidence, Risk Factors, and Outcomes of Intra-Abdominal Hypertension in Critically III Patients—A Prospective Multicenter Study (IROI Study). Critical Care Medicine, 2019, 47, 535-542.	0.9	124
7	A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2005, 48, 2532-2539.	6.3	117
8	Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabetic Medicine, 2000, 17, 667-674.	2.3	113
9	Cohort Profile: The Fremantle Diabetes Study. International Journal of Epidemiology, 2013, 42, 412-421.	1.9	111
10	Is Self-Monitoring of Blood Glucose Appropriate for All Type 2 Diabetic Patients?: The Fremantle Diabetes Study. Diabetes Care, 2006, 29, 1764-1770.	8.6	81
11	A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome. BMC Medical Genetics, 2013, 14, 15.	2.1	73
12	Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia, 2007, 50, 510-515.	6.3	71
13	Effect of insulin therapy on quality of life in Type 2 diabetes mellitus: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2001, 52, 63-71.	2.8	66
14	Excess Risk of Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes. Diabetes Care, 2015, 38, 1274-1280.	8.6	65
15	An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. Internal Medicine Journal, 2010, 40, 286-292.	0.8	63
16	Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia, 2004, 47, 395-399.	6.3	62
17	Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the Fremantle Diabetes Study. Medical Journal of Australia, 2006, 184, 325-328.	1.7	61
18	Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2017, 40, 1548-1555.	8.6	59

#	Article	IF	CITATIONS
19	A systematic review of risk factors for cataract in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2019, 35, e3073.	4.0	58
20	The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. British Journal of Clinical Pharmacology, 2001, 52, 137-144.	2.4	55
21	Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2016, 122, 190-197.	2.8	52
22	A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. International Journal of Pharmacy Practice, 2011, 10, 85-89.	0.6	48
23	Continuing Disparities in Cardiovascular Risk Factors and Complications Between Aboriginal and Anglo-Celt Australians With Type 2 Diabetes. Diabetes Care, 2012, 35, 2005-2011.	8.6	47
24	Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 <scp>A</scp> ustralian cohorts. International Journal of Cancer, 2015, 137, 1699-1708.	5.1	46
25	Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II. Internal Medicine Journal, 2018, 48, 803-809.	0.8	46
26	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Medical Journal of Australia, 2009, 190, 180-184.	1.7	45
27	Fear of falling is common in patients with type 2 diabetes and is associated with increased risk of falls. Age and Ageing, 2015, 44, 687-690.	1.6	43
28	Characteristics and outcome of type 2 diabetes in urban Aboriginal people: the Fremantle Diabetes Study. Internal Medicine Journal, 2007, 37, 59-63.	0.8	38
29	Temporal changes in the prevalence and associates of diabetes-related lower extremity amputations in patients with type 2 diabetes: the Fremantle Diabetes Study. Cardiovascular Diabetology, 2015, 14, 152.	6.8	37
30	Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis. Journal of Diabetes and Its Complications, 2017, 31, 1169-1174.	2.3	37
31	Mid-Life Predictors of Cognitive Impairment and Dementia in Type 2 Diabetes Mellitus: The Fremantle Diabetes Study. Journal of Alzheimer's Disease, 2014, 42, S63-S70.	2.6	33
32	Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I. Diabetologia, 2017, 60, 89-97.	6.3	33
33	Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Medical Journal of Australia, 2009, 191, 47-48.	1.7	32
34	The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?. Diabetes and Metabolism, 2015, 41, 463-469.	2.9	32
35	Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial. PLoS Medicine, 2014, 11, e1001773.	8.4	31
36	A comparison of two methods of foot health education: The Fremantle Diabetes Study Phase II. Primary Care Diabetes, 2015, 9, 155-162.	1.8	29

#	Article	IF	CITATIONS
37	Determinants of Diabetes-Attributable Non-Blood Glucose-Lowering Medication Costs in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2005, 28, 329-336.	8.6	27
38	Comorbid Anxiety and Depression and Their Impact on Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Depression and Anxiety, 2016, 33, 960-966.	4.1	27
39	Temporal Trends in Cardiovascular Complications in People With or Without Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2471-e2482.	3.6	26
40	Prevalence and Predictors of Complementary Medicine Usage in Diabetes: Fremantle Diabetes Study. Journal of Pharmacy Practice and Research, 2003, 33, 260-264.	0.8	25
41	The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study. Internal Medicine Journal, 2006, 36, 155-161.	0.8	24
42	A longitudinal study of foot ulceration and its risk factors in community-based patients with type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2014, 106, 42-49.	2.8	24
43	Depression symptoms are persistent in Type 2 diabetes: risk factors and outcomes of 5â€year depression trajectories using latent class growth analysis. Diabetic Medicine, 2017, 34, 1108-1115.	2.3	24
44	Clinical Features and Outcome in Children with Severe Plasmodium falciparum Malaria: A Meta-Analysis. PLoS ONE, 2014, 9, e86737.	2.5	23
45	Apathy in Older Patients with Type 2ÂDiabetes. American Journal of Geriatric Psychiatry, 2015, 23, 615-621.	1.2	22
46	Economic impact of moderate weight loss in patients with Type 2 diabetes: The Fremantle Diabetes Study. Diabetic Medicine, 2011, 28, 1131-1135.	2.3	21
47	Temporal changes in the prevalence and associates of foot ulceration in type 2 diabetes: The Fremantle Diabetes Study. Journal of Diabetes and Its Complications, 2015, 29, 356-361.	2.3	21
48	Prevalence, risk factors and sequelae of Staphylococcus aureus carriage in diabetes: the Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2015, 29, 1092-1097.	2.3	21
49	Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit. BMJ Open, 2018, 8, e020677.	1.9	21
50	Temporal Trends in Incident Hospitalization for Diabetes-Related Foot Ulcer in Type 2 Diabetes: The Fremantle Diabetes Study. Diabetes Care, 2021, 44, 722-730.	8.6	21
51	Clinical Impact of the Temporal Relationship between Depression and Type 2 Diabetes: The Fremantle Diabetes Study Phase II. PLoS ONE, 2013, 8, e81254.	2.5	20
52	Prevalence of depression and its associations with cardio-metabolic control in Aboriginal and Anglo-Celt patients with type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2015, 107, 384-391.	2.8	19
53	Metabolic memory and allâ€cause death in communityâ€based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes, Obesity and Metabolism, 2016, 18, 598-606.	4.4	19
54	Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2020, 22, 367-373.	4.4	19

#	Article	IF	CITATIONS
55	Cost–effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization, 2011, 89, 211-220.	3.3	18
56	Lifetime depression history and depression risk in type 2 diabetes: A case-control study. Journal of Diabetes and Its Complications, 2016, 30, 38-42.	2.3	18
57	The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II. Medical Journal of Australia, 2017, 207, 344-347.	1.7	18
58	A comparison of obesity indices in relation to mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia, 2020, 63, 528-536.	6.3	18
59	Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2985-2993.	3.6	17
60	Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2017, 134, 153-160.	2.8	17
61	Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes Study. Cardiovascular Diabetology, 2016, 15, 143.	6.8	16
62	A 10-Year Prospective Study of Bone Mineral Density and Bone Turnover in Males and Females With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3531-3539.	3.6	16
63	Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes, Obesity and Metabolism, 2018, 20, 2852-2859.	4.4	16
64	Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. Cardiovascular Diabetology, 2020, 19, 43.	6.8	16
65	Diagnostic Criteria for Depression in Type 2 Diabetes: A Data-Driven Approach. PLoS ONE, 2014, 9, e112049.	2.5	14
66	Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study. Journal of Alzheimer's Disease, 2017, 56, 1127-1133.	2.6	14
67	Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2019, 33, 107406.	2.3	14
68	Prevalence and prognosis of a low serum testosterone in men with type 2 diabetes: the Fremantle Diabetes Study Phase II. Clinical Endocrinology, 2016, 85, 444-452.	2.4	13
69	Prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults: The Fremantle Diabetes Study Phase II. Clinical Endocrinology, 2020, 92, 373-382.	2.4	13
70	A populationâ€based study of the association between dysglycaemia and hearing loss in middle age. Diabetic Medicine, 2017, 34, 683-690.	2.3	12
71	Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2018, 32, 400-405.	2.3	12
72	Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I. Diabetes Care, 2019, 42, 102-109.	8.6	12

#	Article	IF	CITATIONS
73	Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II. BMJ Open Diabetes Research and Care, 2020, 8, e000983.	2.8	12
74	Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E696-E700.	3.6	11
75	Risk of suicide in Australian adults with diabetes: the Fremantle Diabetes Study. Internal Medicine Journal, 2015, 45, 976-980.	0.8	11
76	A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1119-1127.	1.6	11
77	Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study. Acta Diabetologica, 2019, 56, 767-776.	2.5	11
78	The Structured Interview for Insight and Judgment in Dementia: Development and validation of a new instrument to assess awareness in patients with dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 24-32.	2.4	10
79	Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2019, 42, 288-296.	8.6	10
80	The relationship between carotid disease and retinopathy in diabetes: a systematic review. Cardiovascular Diabetology, 2020, 19, 54.	6.8	10
81	Communityâ€based management of complex type 2 diabetes: adaptation of an integrated model of care in a general practice setting. Internal Medicine Journal, 2021, 51, 62-68.	0.8	10
82	Determinants and costs of community nursing in patients with type 2 diabetes from a community-based observational study: The Fremantle Diabetes Study. International Journal of Nursing Studies, 2013, 50, 1166-1171.	5.6	9
83	Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 551-559.	3.6	9
84	The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2018, 143, 62-70.	2.8	9
85	Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes: the Fremantle Diabetes Study Phase II. Diabetic Medicine, 2020, 37, 1688-1695.	2.3	9
86	Influence of Renin-Angiotensin System Inhibitors on Lower–Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2020, 43, 2113-2120.	8.6	9
87	Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study. Malaria Journal, 2015, 14, 121.	2.3	8
88	Circulating osteocalcin is unrelated to glucose homoeostasis in adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 948-951.	2.3	8
89	Clinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes Study. Diabetic Medicine, 2018, 35, 903-910.	2.3	8
90	Cardiovascular risk prediction in adults with type 1 diabetes: The Fremantle Diabetes Study. Diabetes Research and Clinical Practice, 2010, 90, e75-e78.	2.8	7

#	Article	lF	CITATIONS
91	Dose–response relationship between statin therapy and glycaemia in communityâ€based patients with type 2 diabetes: the <scp>F</scp> remantle <scp>D</scp> iabetes <scp>S</scp> tudy. Diabetes, Obesity and Metabolism, 2016, 18, 1143-1146.	4.4	7
92	Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: The Fremantle diabetes study. Journal of Diabetes and Its Complications, 2017, 31, 945-947.	2.3	7
93	The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2018, 142, 294-302.	2.8	7
94	Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care, 2020, 43, 3034-3041.	8.6	7
95	PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Journal of Clinical Medicine, 2020, 9, 3212.	2.4	7
96	Contemporary Cardiovascular Risk Assessment for Type 2 Diabetes Including Heart Failure as an Outcome: The Fremantle Diabetes Study Phase II. Journal of Clinical Medicine, 2020, 9, 1428.	2.4	7
97	Intra-abdominal hypertension and hypoxic respiratory failure together predict adverse outcome – A sub-analysis of a prospective cohort. Journal of Critical Care, 2021, 64, 165-172.	2.2	7
98	Incidence and predictors of idiopathic pulmonary fibrosis complicating <scp>Type 2</scp> diabetes: the <scp>Fremantle Diabetes Study Phase</scp> I. Internal Medicine Journal, 2021, 51, 276-279.	0.8	6
99	Wound healing with "sprayâ€on―autologous skin grafting ( ReCell ) compared with standard care in patients with large diabetesâ€related foot wounds: an openâ€abel randomised controlled trial. International Wound Journal, 2021, , .	2.9	6
100	Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the <scp>Australian National Diabetes Audit</scp> from 2013 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 2603-2613.	4.4	6
101	The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II. PLoS ONE, 2018, 13, e0194417.	2.5	6
102	Apolipoprotein E genotype and mortality in Southern European and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. European Journal of Endocrinology, 2010, 163, 559-564.	3.7	5
103	The interactive effects of type 2 diabetes mellitus and schizophrenia on all-cause mortality: The Fremantle Diabetes Study. Journal of Diabetes and Its Complications, 2015, 29, 1320-1322.	2.3	5
104	Changes in characteristics and management of <scp>A</scp> sian and <scp>A</scp> ngloâ€ <scp>C</scp> elts with type 2 diabetes over a 15â€year period in an urban <scp>A</scp> ustralian community: The <scp>F</scp> remantle <scp>D</scp> iabetes <scp>S</scp> tudy. Journal of Diabetes, 2016, 8, 139-147.	1.8	5
105	Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study. Diabetes, Obesity and Metabolism, 2019, 21, 648-657.	4.4	5
106	Successful Withdrawal of Insulin Therapy After Post-Treatment Clearance of Hepatitis C Virus in a Man with Type 2 Diabetes. American Journal of Case Reports, 2017, 18, 414-417.	0.8	5
107	The association between carotid disease, arterial stiffness and diabetic retinopathy in type 2 diabetes: the Fremantle Diabetes Study Phase II. Diabetic Medicine, 2021, 38, e14407.	2.3	4
108	Cognitive Impairment in People with Diabetes-Related Foot Ulceration. Journal of Clinical Medicine, 2021, 10, 2808.	2.4	4

#	Article	IF	CITATIONS
109	Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase <scp>II</scp> . Internal Medicine Journal, 2017, 47, 1206-1210.	0.8	3
110	Subjective memory complaints are not increased in type 2 diabetes: A matched cohort study. Journal of Diabetes and Its Complications, 2019, 33, 424-426.	2.3	3
111	Spray on skin for diabetic foot ulcers: an open label randomised controlled trial. Journal of Foot and Ankle Research, 2019, 12, 52.	1.9	3
112	Complementary medicine use and its cost in Australians with type 2 diabetes: the Fremantle Diabetes Study Phase II. Internal Medicine Journal, 2020, 50, 944-950.	0.8	3
113	Differences in retinopathy prevalence and progression between Anglo elt and Aboriginal Australians: The Fremantle Diabetes Study Phase II. Internal Medicine Journal, 2020, , .	0.8	3
114	Assessment of biomarkers associated with rapid renal decline in the detection of retinopathy and its progression in type 2 diabetes: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2021, 35, 107853.	2.3	3
115	Prevalence, Incidence and Associates of Pulmonary Hypertension Complicating Type 2 Diabetes: Insights from the Fremantle Diabetes Study Phase 2 and National Echocardiographic Database of Australia. Journal of Clinical Medicine, 2021, 10, 4503.	2.4	3
116	Complementary and alternative medicine beliefs in type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes Research and Clinical Practice, 2020, 166, 108311.	2.8	2
117	Knowledge of ocular complications of diabetes in community-based people with type 2 diabetes: The Fremantle Diabetes Study II. Primary Care Diabetes, 2021, 15, 554-560.	1.8	2
118	The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with <i>Plasmodium knowlesi</i> malaria. British Journal of Clinical Pharmacology, 2022, 88, 691-701.	2.4	2
119	Pharmacokinetic properties of the antimalarial combination therapy artemether–lumefantrine in normal-weight, overweight and obese healthy male adults. International Journal of Antimicrobial Agents, 2022, 59, 106482.	2.5	2
120	Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of \$169 572 per QALY and exenatide with \$278 935 per QALY as second-line treatment in adult diabetics in the USA. Evidence-Based Medicine, 2010, 15, 40-41.	0.6	1
121	Re: Essential Service Standards for Equitable National Cardiovascular Care for Aboriginal and Torres Strait Islander People. Heart Lung and Circulation, 2015, 24, 626.	0.4	1
122	Cost-effectiveness of artemisinin–naphthoquine versus artemether–lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children. Malaria Journal, 2017, 16, 438.	2.3	1
123	The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?. Journal of Diabetes and Its Complications, 2019, 33, 427-433.	2.3	1
124	Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study. Journal of Clinical Medicine, 2020, 9, 3409.	2.4	1
125	Incidence and predictors of vision loss complicating type 2 diabetes: The Fremantle Diabetes Study Phase II. Journal of Diabetes and Its Complications, 2020, 34, 107560.	2.3	1
126	Relative incidence and predictors of pulmonary arterial hypertension complicating type 2 diabetes: The Fremantle Diabetes Study Phase I. Journal of Diabetes and Its Complications, 2021, 35, 107773.	2.3	1

#	Article	IF	CITATIONS
127	A prospective six-month audit of inpatient hypoglycemia in step-down general medical and geriatric wards. International Journal of Medical Sciences, 2021, 18, 3744-3747.	2.5	1
128	Temporal Trends in Renal Replacement Therapy in Community-Based People with or without Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Medicine, 2022, 11, 695.	2.4	1
129	Re: Subclinical thyroid dysfunction and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1474.	2.3	0
130	Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study. Internal Medicine Journal, 2018, 48, 1215-1221.	0.8	0
131	Response to Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102–109. Diabetes Care, 2019, 42, e101-e101.	8.6	0